BUSINESS WIRE
Company’s First Ophthalmic Product, A Significant New Class of
Lubricant Eye Drop for Dry Eye Patients, Receives CE Mark
HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH, a drug delivery company with a focus on the topical
application of ophthalmic technologies for poorly soluble drugs, today
announced the successful CE mark approval for the first topical eye
lubricant based on Novaliq’s proprietary technology EyeSol™.
NovaTears™ OTC is a multi-dose, non-aqueous, non-blurring and
preservative-free topical eye drop for lubrication of the ocular surface.
“We are pleased to receive CE mark approval for our first ophthalmic
product designed to improve the quality of life for the dry eye OTC
patient,” said Bernhard Guenther, CEO of Novaliq GmbH. “It offers a
significant new product choice for the European consumer; innovative
Novaliq technology that contains no preservatives, yet is available in
conventional, multi-dose bottles. The absence of irritating surfactants
and preservatives provides dry eye patients improved tolerability and
convenience.”
This is the first new product from Novaliq GmbH since the company raised
€13.9 million ($18.1 million) in its 5th round of financing
in April 2013, funding the ongoing development of its ophthalmic
portfolio which includes CyclASol Rx, the first planned Novaliq
prescription product, as well as additional OTC products.
“We congratulate Novaliq on obtaining the CE mark for NovaTears OTC and
look forward to future product additions to the SFA portfolio,”
commented Mathias Hothum, Managing Director of Dievini Hopp Bio Tech
Holding GmbH & Co., the investment company of SAP established with
co-founder Dietmar Hopp. “We are pleased to help Novaliq further its
pioneering ocular drug delivery technology and strong management team.”
Novaliq GmbH is a drug delivery company that is developing a superior
generation of ocular formulations for poorly soluble drugs. The patented
ocular formulations are based on semifluorinated alkanes (SFAs), which
can be easily applied in the form of topical eye drops. A new generation
of both prescription and consumer ocular products is possible through
the unique and proprietary properties of SFAs as a delivery vehicle.
Novaliq’s strategy is to establish a portfolio of consumer and
prescription products in the field of ophthalmology. These products are
intended to cover unmet needs with one major advantage being they will
be preservative free.
Dievini is an active investor in Life and Health Sciences companies,
with a focus on innovative therapeutics and diagnostics shown to lead to
novel treatment regimens, allowing doctors to treat patients with
life-threatening diseases better and safer than they can today.
About Novaliq GmbH
Novaliq is a drug delivery company whose goal is to develop innovative
pharmaceutical formulations. Its patented semifluorinated alkanes (SFAs)
can be used in various routes of administration for the transport of
drugs or oxygen for therapeutic purposes. Based on its unique
physicochemical properties, Novaliq currently develops innovative
ophthalmic formulations as well as solutions for organ preservation and
has several product candidates with excellent market potential in
various stages of development.
Novaliq welcomes invitations from interested parties to enter into
discussions about significant additional development or partnership
opportunities.